Acutus Medical

Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. It creates electrophysiological mapping systems for the treatment of cardiac arrhythmias, such as atrial fibrillation, and ventricular tachycardia. The company was founded by Randell L. Werneth and Christoph Scharf in 2011 and is headquartered in Carlsbad, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) investors concerning the Company's possible violations of federal securities laws. On November 11, 2021, Acutus announced that it was slashing its 2021 revenue guidance from a range of $22 million to $33 million down to a range of $17 million to $17.5 million. The Company attributed the revision in substantial part to on the Compa

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acutus Medical, Inc. (AFIB) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) on behalf of investors concerning the Company's possible violations of federal securities laws.. If you are a shareholder who suffered a loss, click here to participate. On November 11, 2021, Acutus announced that it was slashing its 2021 revenue guidance from a range of $22 million to $33 million down to a range of $17 million to $17.5 mil

The Law Offices of Frank R. Cruz Announces Investigation of Acutus Medical, Inc. (AFIB) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - February 16, 2022) -  Holzer & Holzer, LLC informs investors that on February 15, 2022 a class action lawsuit was filed against Acutus Medical, Inc. ("Acutus Medical" or the "Company") (NASDAQ: AFIB). The lawsuit alleges Acutus Medical made false and/or misleading statements, including, but not limited to, the Company's failure to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to...

SHAREHOLDER ALERT: Holzer & Holzer Encourages Acutus Medical, Inc. (AFIB) Investors With Significant Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022. SO WHAT: If you purchased Acutus Medical securities during the Class Pe

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Acutus Medical, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AFIB

SAN DIEGO--(BUSINESS WIRE)-- #AFIBstock--The suit alleges defendants issued false statements concerning Acutus business and prospects, resulting in its stock trading at inflated prices.

AFIB ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc. and Announces Opportunity for Investors With Substantial Losses to Lead Case

San Diego, California--(Newsfile Corp. - January 26, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Acutus Medical, Inc. ("Acutus " or "the Company") (NASDAQ: AFIB).On or around August 6, 2020, Acutus conducted its initial public offering ("IPO"), issuing 8,800,000 shares priced at $18.00 per share. Then, on March 19, 2021, analysts at both William Blair and JPMorgan downgraded Acutus's stock, citing the Company's weaker...

(AFIB) News: Did You Lose Money on Your Acutus Medical Stock? Contact Johnson Fistel Regarding Class Action Investigation

CARLSBAD, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced a corporate restructuring as well as its preliminary unaudited revenue for the quarter and full year ended December 31, 2021.

Acutus Medical Announces Restructuring and Preliminary, Unaudited Fourth Quarter and Full Year 2021 Revenue

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the company's attendance at the 27th Annual AF Symposium.

Acutus Medical's Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium

Cango Inc - ADR

There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation value.

A Duo of Net Current Asset Value Stocks to Consider

The stock price of Acutus Medical Inc (NASDAQ: AFIB) fell over 25% pre-market today. This is why it happened.

Acutus Medical (AFIB) Stock: Why The Price Dropped Today

Acutus Medical's (AFIB) CEO Vince Burgess on Q3 2021 Results - Earnings Call Transcript

Acutus Medical (NASDAQ:AFIB) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Recap: Acutus Medical Q3 Earnings

Acutus' Catheter-Based Therapy Platform, AcQBlate Force, Will Integrate Multiple Ablation Modalities Guided by Novel Noncontact Mapping Technology to Treat Complex Atrial Arrhythmias Acutus' Catheter-Based Therapy Platform, AcQBlate Force, Will Integrate Multiple Ablation Modalities Guided by Novel Noncontact Mapping Technology to Treat Complex Atrial Arrhythmias

Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation

CARLSBAD, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2021.

Acutus Medical Reports Third Quarter 2021 Financial Results

Acutus Medical, Inc. (AFIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Acutus Medical, Inc. (AFIB) to Report a Decline in Earnings: What to Look Out for

CARLSBAD, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the third quarter of 2021 on Thursday, November 11, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Third Quarter 2021 Financial Results

Acutus Medical, Inc. (AFIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Acutus Medical, Inc. (AFIB) Moves 9.6% Higher: Will This Strength Last?

Acutus Medical, Inc.'s superior contactless mapping technology threatens to change and expand the ablation treatment paradigm for cardiac arrhythmias. However, the company's launch has been disappointing with the pandemic being held out as the scapegoat.

Acutus Medical: A Name To Slowly Accumulate

Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q2 2021 Results - Earnings Call Transcript

CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021.

Acutus Medical Appoints Niamh Pellegrini to Board of Directors

CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2021.

Acutus Medical Reports Second Quarter 2021 Financial Results

CARLSBAD, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.

Acutus Medical to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

CARLSBAD, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the second quarter of 2021 on Thursday, August 12, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Second Quarter 2021 Financial Results

MOUNTAIN VIEW, Calif., July 27, 2021 /PRNewswire/ -- AliveCor, Inc. ("AliveCor"), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, and Acutus Medical ("Acutus") (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced they will collaborate to assess the integration of data collection tools across the cardiology continuum of care that could potentially advance the field of arrhythmia treatment and disease management.

AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias

CARLSBAD, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”) today announced that the underwriter of its previously announced public offering, which closed on July 19, 2021, have exercised in full its option to purchase 825,000 additional shares of common stock from Acutus at the public offering price of $14.00 per share, less underwriting discounts and commissions. The closing of the option exercise occurred on July 26, 2021. With the addition of the full exercise of the underwriter's option to purchase additional shares, the total number of shares sold by Acutus in the offering increased to 6,325,000 shares, and the aggregate gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, were approximately $88.6 million.

News for Acutus Medical Stock (AFIB)